Dylan O'Sullivan

Dr. Dylan O'Sullivan



Adjunct Assistant Professor

Cumming School of Medicine, Department of Oncology

Adjunct Assistant Professor

Cumming School of Medicine, Department of Community Health Sciences


Arnie Charbonneau Cancer Institute

Contact information


Educational Background

BA Sociology, Dartmouth College, 2015

PhD Epidemiology, Queen's University, 2020


Dr. Dylan O’Sullivan is a cancer epidemiologist and health services researcher in the Department of Cancer Epidemiology and Prevention Research (CEPR) of Cancer Care Alberta, Alberta Health Services and an adjunct assistant professor in the Departments of Oncology and Community Health Sciences at the University of Calgary. Dr. O’Sullivan completed a BA in Sociology at Dartmouth College (U.S.), where he competed on the varsity cross country and track and field teams. He then completed a mini-Master’s in Epidemiology in 2016 and a PhD in Public Health Sciences (Epidemiology) at Queen’s University in 2020. Between 2020 and 2022, Dr. O’Sullivan completed a Canadian Institutes of Health Research (CIHR)-funded postdoctoral fellowship at the University of Calgary, where his research focused on reducing the incidence and improving outcomes of early-onset colorectal cancer patients (< 50 years of age) with an interdisciplinary research approach.


Areas of Research

Area of Focus
  • Early-onset colorectal cancer, cancer prevention research
  • Colorectal cancer screening, real-world treatment patterns and outcomes
  • Molecular testing and patient outcomes
Summary of Research

Dr. Dylan O’Sullivan is a cancer epidemiologist and a health services researcher with a background in molecular epidemiology. Dr. O’Sullivan’s research program is aimed at reducing the cancer burden across the full cancer control continuum (prevention, screening, and outcomes) with the use of existing methods and the development of novel data analytics. For primary prevention, his research includes the examination of incidence and mortality trends, population attributable risk estimation, etiologic research using data from case-control and prospective cohort studies, as well as molecular studies using novel data analytics to identify emerging risk factors and to determine biological mechanisms of carcinogens. For secondary prevention his research includes the assessment of the impact of current screening programs and risk prediction for improved screening using administrative and laboratory data. Finally, for tertiary prevention his work focuses on real-world treatment patterns and outcomes, the development of prognostic and predictive models, comparative effectiveness using real-world data, and the assessment of the impact of molecular testing on patient outcomes.